A Clinical Case Study on the Long Term Respiration Management of Amyotrophic Lateral Sclerosis Patient with Respiratory Failure

Jong Cheol Lee; Ho Hyun Jeong; Eun Hye Cha; Man Yong Park; Tae Ho Kim; Bong Keun Song; Il Hong Son; Sung Chul Kim

doi:10.13045/acupunct.2014044

J Acupunct Res > Volume 31(3); 2014 > Article

Lee, Jeong, Cha, Park, Kim, Song, Son, and Kim: A Clinical Case Study on the Long Term Respiration Management of Amyotrophic Lateral Sclerosis Patient with Respiratory Failure※

Case Report

The Acupuncture 2014; 31(3): 67-73.

Published online: September 20, 2014

DOI: https://doi.org/10.13045/acupunct.2014044

A Clinical Case Study on the Long Term Respiration Management of Amyotrophic Lateral Sclerosis Patient with Respiratory Failure^※

Jong Cheol Lee^1,², Ho Hyun Jeong^1,², Eun Hye Cha^1,², Man Yong Park^1,², Tae Ho Kim³, Bong Keun Song⁴, Il Hong Son⁵, Sung Chul Kim^1,^2,^*

¹Department of Acupuncture & Moxibustion Medicine, Gwangju Korean Medical Hospital, Wonkwang University

²Amyotrophic Lateral Sclerosis Center, Gwangju Korean Medical Hospital, Wonkwang University

³Department of Acupuncture & Moxibustion Medicine, Bucheon Jaseng Hospital of Korean Medicine

⁴Department of Internal Medicine, Gwangju Korean Medical Hospital, Wonkwang University

⁵Department of Neurology, Sanbon Hospital, Wonkwang University

^* Corresponding author : Department of Acupuncture & Moxibustion Medicine, Gwang-Ju Oriental Medical Hospital, Wonkwang University, 1140-23, Hoejae-ro, Nam-gu, Gwangju, 503-832, Republic of Korea, Tel : +82-62-670-6441 E-mail : kscndl@hanmail.net

Received August 11, 2014 Revised August 28, 2014 Accepted August 28, 2014

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

See the Original "".

Abstract

Objectives:

Amyotrophic lateral sclerosis(ALS) is a progressive neurodegenerative disorder characterized by a selective death of motor neuron, leading to respiratory insufficiency. The purpose of this study was to assess the long term respiratory management of ALS patient with respiratory failure.

Methods:

One ALS patient applying a non-invasive BIPAP ventilator as well as Korean medical treatment such as acupuncture, pharmacopuncture and herbal medicine was measured on SpO₂, EtCO₂, Vte(expiratorytidalvolume) for 2 years 7 months.

Results:

The SpO₂, EtCO₂ of ALS patient were maintained in the normal range for 2 years 7 months. The Vte of ALS patient also wasn’t worse in this study.

Conclusions:

In this study, the long term respiration management, combined administration of Korean medical treatment and non-invasive BIPAP ventilator, could be effective in ALS patient with respiratory failure.

Key Words: Amyotrophic lateral sclerosis(ALS); Respiratory failure; Non-invasive BIPAP ventilator; Oriental medical treatment; EtCO₂; SpO₂.

Notes

This study was supported by a grant of the Korean Health Technology R & D Project through the Korea Health Industry Development Institute(KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number : HI11C2142)

Fig. 1.

The changes in Vte for respiratory management

Fig. 2.

The changes in SpO₂, EtCO₂ and RR for respiratory management

Table 1.

Respiratory Progress

	PS (cmH₂O)	Vte (ml)	SpO₂ (%)	EtCO₂ (mmHg)	RR (BPM)
2011. 11. 10	7	-	96	39.5	23.5
2011. 12. 12	10	1,100	97	33	15.5
2012. 01. 12	12	1,000	97	34	14.5
2012. 02. 13	12	1,050	98	32.5	14
2012. 03. 12	12	1,175	97	33.5	16.5
2012. 04. 12	12	1,200	97	35.5	14.5
2012. 05. 11	12	1,100	98	32	15
2012. 06. 13	12	1,500	97	33	14
2012. 07. 13	12	1,050	96	31.5	16
2012. 08. 13	12	1,050	96	32	16
2012. 09. 13	12	1,250	95	32	16
2012. 10. 12	12	1,350	97	28	14
2012. 11. 13	12	1,140	97	34	14
2012. 12. 13	12	1,300	96	29.5	17
2013. 01. 14	12	900	97	31	14
2013. 02. 13	12	1,800	97	35	14
2013. 03. 13	12	1,050	96	32	15
2013. 04. 11	12	1,000	97	-	16
2013. 05. 13	14	1,400	96	27	14
2013. 06. 13	14	1,500	97	28	15
2013. 07. 12	14	1,000	96	28	14.5
2013. 08. 13	14	1,325	98	29	17
2013. 09. 13	14	1,650	98	27	16
2013. 10. 14	14	1,600	98	28	17
2013. 11. 13	14	1,650	98.5	28.5	19.5
2013. 12. 13	14	1,950	99	-	-
2014. 01. 14	14	1,400	98	34.5	17
2014. 02. 13	14	1,400	98	28	15
2014. 03. 13	14	1,650	99	26	15
2014. 04. 14	14	1,625	99	35	15
2014. 05. 14	14	1,550	99	28	17
2014. 06. 13	14	1,500	99	26	15
2014. 07. 14	14	1,350	94.5	24	16.5

PS : pressure support.

VTe : exhaled tidal volume.

SpO₂ : peripheral oxygen saturation.

EtCO₂ : end-tidal carbon dioxide.

RR : respiration rate.

If the raw data was measured a range form, it was filled in means for our convenience.

IV. References

1. Gordon Paul H. Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging and Disease. 2013;4(5):295–310.

2. Kim SH. Diagnosis and therapeutic strategies of amyotrophic lateral sclerosis. Hanyang Medical Reviews. 2006;26(1):45–51.

3. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118(3):707–19.

4. Caroscio JT, Mulvihill MN, Sterling R, Abrams B. Amyotrophic lateral sclerosis, its natural history. Neurol Clin. 1987;5(1):1–9.

5. Mulder DW. Motor neuron disease. Edited by Dyck PJ, Thomas PK, Lambert EH, Bunge R. In: Peripheral neuropathy. 2. 2. Philadelphia PA: WB Saunders. 1984:1525–36.

6. Radunovic A, Annane D, Rafiq MK, Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Database of Systemic Reviews. 2013;published online 28. 3.

7. Gordon PH, Corcia P, Lacomblez L, et al. Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol. 2009;66(6):758–61.

8. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013):1425–31.

9. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585–91.

10. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease(MND). Cochrane Database Syst Rev. 2012;published online 14. 3.

11. Gordon PH, Mitsumoto H. Chapter 20 symptomatic therapy and palliative aspects of clinical care. Handb Clin Neurol. Netherlands: North-Holland Pub Co.. 2008:389–424.

12. Heckmatt JZ, Loh L, Dubowitz V. Night-time nasal ventilation in neuromuscular disease. Lancet. 1990;335(8689):579–82.

13. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5(2):140–7.

14. Lee S, Kim S. The effects of Sa-am acupuncture treatment on respiratory phsiology parameters in amyotrophic lateral sclerosis patients: a pilot study. Evid Based Complement alternat Med. 2013:published online 11. 9.

15. Tandan R, Bradley WG. Amyotrophic lateral sclerosis: part 1. clinical features, pathology, and ethical issues in management. Ann Neurol. 1985;18(3):271–80.

16. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688–700.

17. Del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003;60(5):813–19.

18. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies(an evidencebased review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2009;73(24):1218–26.

19. Morgan RK, McNally S, Alexander M, Conroy R, Hardiman O, Costello RW. Use of sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2005;171(3):269–74.

20. Baumann F, Henderson RD, Morrison SC, et al. Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph lateral sclera. 2010;(1–2):194–202.

21. Newsom-Davis IC, Lyall RA, Leigh PN, Moxham J, Goldstein LH. The effect of non-invasive positive pressure ventilation(NIPPV) on cognitive function in amyotrophic lateral sclerosis(ALS): a prospective study. J Neurol Neurosurg Psychiatry. 2001;71(4):482–7.

22. Heiman-Patterson TD, Miller RG. NIPPV: a treatment for ALS whose time has come. Neurology. 2006;67(5):736–7.

23. Korean acupuncture & Moxibustion Medicine Society Textbook Compailation Commitee. Korean acupuncture & moxibustion medicine Ha volume. Gyeonggi: Jipmoondang. 2008:197–200.

24. Heo J. Donguibogam. Seoul: Yeogang Publishing Company. 1994:1060–1, 1102–3.

25. Kim DH. Illustrations Kyokam Sa-am Do-in acupuncture. Busan: Sogang. 2002:475–80.

26. Wade OL. Movements of the thoracic cage and diaphragm in respiration. The Journal of physiology. 1954;124(2):193.

27. Barrett Kim E, Barman Susan M, Boitano Scott, Brooks Heddwen. “35. Pulmonary Function”. Ganong's review of medical physiology. 23rd edition. USA: McGraw-Hill Companies, Incorporated. 2009:Cite uses deprecated parameters(587–638 help).

28. Campbell EJM. The role of the scalene and sternomastoid muscles in breathing in normal subjects. An electromyographic study. Journal of Anatomy. 1955;89(3):378–86.

29. Netter FH. Atlas of human anatomy. 3rd ed. Icon learning systems. Teterboro. New Jersey: Icon learning systems. 2003:191.

30. Raper AJ, Thompson WT, Shapiro W, Patterson JL. Scalene and sternomastoid muscle function. Journal of Applied Physiology. 1966;21(2):497–502.

31. De Troyer A. Respiratory muscle function. Edited by Gibson J, Geddes DM, Costabel U. In: Respiratory medicine. London: Saunders. 2003:119–29.

32. Rakhit R, Cunningham P, Furtos-Matei A, et al. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem. 2002;277(49):47551–6.

33. Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu, Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res. 1995;676(1):25–40.

34. Nguyen MD, Lariviere RC, Julien JP. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron. 2001;30(1):135–47.

35. MuDan Cai, Choi SM, Song BK, Son IH, Kim SC, Yang EJ. Scolopendra subspinipes mutilans attenuates neuroinflammation in symptomatic hSOD1^G93A mice. Journal of Neuroinflammation. 2013;10(1):131.

36. Lee SH, Choi SM, Yang EJ. Melittin ameliorates the inflammation of organs in an amyotrophic lateral sclerosis animal model. Exp Neurobiol. 2014;Mar;23(1):86–92.

37. Gammage GW, Banner MJ, Blanch PB, et al. Ventilator displayed tidal volume: what you see may not be what you get. Crit Care Med. 1988;16(4):454.